Assessing risk factors in patients with pulmonary arterial hypertension
Multi-marker Approach for Risk Assessment in Pulmonary Arterial Hypertension (PAH)
This study is trying to gather information about patients with pulmonary arterial hypertension in China to see how their condition changes over time and what treatments work best for them.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 1 Year to 85 Years |
| Sex | All |
| Sponsor | Wuhan Asia Heart Hospital Academic / other |
| Locations | 1 site (Wuhan) |
| Trial ID | NCT03954405 on ClinicalTrials.gov |
What this trial studies
This observational study aims to create a prospective registry of patients diagnosed with pulmonary arterial hypertension (PAH) in China. It will collect data on clinical characteristics, treatment trends during hospitalization, and long-term outcomes over a ten-year period, focusing on major adverse cardiovascular events (MACE). Key assessments will include echocardiograms, lung function tests, right heart catheterization, and exercise capacity measurements. The study will also track changes in patients' functional class and treatment responses.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals diagnosed with pulmonary arterial hypertension confirmed by right heart catheterization.
Not a fit: Patients who refuse to participate in the study will not benefit from its findings.
Why it matters
Potential benefit: If successful, this study could enhance understanding of PAH and improve risk assessment and management strategies for patients.
How similar studies have performed: Other studies have shown success in using multi-marker approaches for risk assessment in cardiovascular diseases, suggesting potential for this methodology in PAH.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: diagnosis of PAH (by RHC) Exclusion Criteria: Refusal to participate.
Where this trial is running
Wuhan
- Wuhan Asian Heart Hospital — Wuhan, China (Recruiting)
Study contacts
- Principal investigator: Qiu Qiu — Wuhan Asian Heart Hospital
- Study coordinator: Zheng Xusn
- Email: soniazheng@outlook.com
- Phone: +8618627885144
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.